AngioDynamics/$ANGO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AngioDynamics
AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Med Tech includes Auryon and Thrombectomy, while Med Device has Peripheral Products (Interventional Devices), Ports, and Microwave Ablation. Geographically operates in the USA and Other countries; maximum revenue from the USA.
- Ticker
- $ANGO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 632
- Headquarters
- Latham, United States
- Website
- www.angiodynamics.com
AngioDynamics Metrics
BasicAdvanced
$493M
-
-$0.79
0.30
-
Price and volume
Market cap
$493M
Beta
0.3
52-week high
$16.29
52-week low
$9.39
Average daily volume
927K
Financial strength
Current ratio
2.396
Quick ratio
1.321
Long term debt to equity
0.054
Total debt to equity
0.065
Interest coverage (TTM)
-54.54%
Profitability
EBITDA (TTM)
1.313
Gross margin (TTM)
55.28%
Net profit margin (TTM)
-10.12%
Operating margin (TTM)
-6.42%
Effective tax rate (TTM)
-0.54%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
-5.14%
Return on equity (TTM)
-19.21%
Valuation
Price to revenue (TTM)
1.505
Price to book
3.04
Price to tangible book (TTM)
4.88
Price to free cash flow (TTM)
339.057
Free cash flow yield (TTM)
0.29%
Free cash flow per share (TTM)
0.035
Growth
Revenue change (TTM)
8.20%
Earnings per share change (TTM)
0.89%
3-year revenue growth (CAGR)
-1.05%
10-year revenue growth (CAGR)
-0.92%
3-year earnings per share growth (CAGR)
69.58%
10-year earnings per share growth (CAGR)
-3.65%
What the Analysts think about AngioDynamics
Analyst ratings (Buy, Hold, Sell) for AngioDynamics stock.
Analyst projections of the future price of AngioDynamics stock.
Bulls say / Bears say
Med Tech is growing much faster than the legacy business: it rose 13.2% in the latest quarter, led by Auryon up 14.7%, AlphaVac up 37.4% and NanoKnife up 29%. Auryon has now delivered 21 consecutive quarters of double-digit growth. (AngioDynamics)
NanoKnife has room to expand as coverage and clinical evidence build. Humana extended coverage to eligible patients under Medicare criteria, while a new pancreatic IRE billing code takes effect in January 2027; published study results also reported longer survival associated with IRE, though the study was not randomised. (AngioDynamics, AngioDynamics)
The business is showing better adjusted operating performance: quarterly adjusted EBITDA rose to $5.0 million from $2.2 million a year earlier. AngioDynamics has no debt and expects positive operating cash flow for fiscal 2027, which could support its investment in growth products. (AngioDynamics, AngioDynamics)
Growth is modest at group level and increasingly reliant on Med Tech: first-quarter sales rose 6.9%, while management expects fiscal 2027 Med Device sales to be flat and total sales growth of only about 5% to 6.5%. That leaves little room for the faster-growing platforms to stumble. (AngioDynamics)
Profitability and cash generation remain fragile: AngioDynamics reported a $7.1 million GAAP loss and used $15.3 million of operating cash in the quarter. The 59.4% gross margin benefited from tariff refunds, and management expects lower gross margins in the second half of fiscal 2027 while still guiding to an adjusted full-year loss per share. (SEC, AngioDynamics)
The legacy port business carries a material legal overhang: the company was defending about 430 product-liability claims involving its port products as of 31 August 2026. The filings note that further claims or information could materially affect its estimates of exposure. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
AngioDynamics Financial Performance
Revenues and expenses
AngioDynamics Earnings Performance
Company profitability
Upcoming events
No upcoming events
AngioDynamics News
AllArticlesVideos
AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 days ago
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
Business Wire4 weeks ago
AngioDynamics Stock Is Falling Thursday: What's Going On?
Benzinga1 month ago
Funds containing AngioDynamics
Fund name | Fund size | $ANGO weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.